Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Planchard

Showing results (91-100 of 243) with videos related to

Pageof 25
Sort By:
European Journal of Cancer (Oxford, England : 1990)|April 16, 2023
Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: real-world dataAlice Boilève, Matthieu Faron, Sarah Fodil-Cherif, et al.
Nature Communications|September 2, 2021
Integrin-α<sub>V</sub>-mediated activation of TGF-β regulates anti-tumour CD8 T cell immunity and response to PD-1 blockadeInes Malenica, Julien Adam, Stéphanie Corgnac, et al.
JAMA Network Open|September 10, 2025
Concomitant Comedications and Survival With First-Line Pembrolizumab in Advanced Non-Small-Cell Lung CancerAdrien Rousseau, Noémie Simon-Tillaux, Stefan Michiels, et al.
Clinical and Translational Radiation Oncology|May 19, 2023
Stereotactic body radiotherapy for extra-cranial oligoprogressive or oligorecurrent small-cell lung cancerAntonin Levy, Jonathan Khalifa, Etienne Martin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 17, 2019
Characterization, Prognosis, and Treatment of Patients With Metastatic Lung Carcinoid TumorsPatrick Robelin, Julien Hadoux, Julien Forestier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 15, 2013
Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancerEmma Pailler, Julien Adam, Amélie Barthélémy, et al.
Frontiers in Immunology|November 10, 2022
Immune-related arthritis following pelvic radiation therapy in a patient with lung cancer receiving long-term immune checkpoint blocker treatment: Case reportMihaela Aldea, Rakiba Belkhir, Emeline Colomba, et al.
Cancer Chemotherapy and Pharmacology|February 24, 2016
Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studiesDavid Planchard, Kathryn H Brown, Dong-Wan Kim, et al.
NPJ Precision Oncology|July 17, 2021
Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitorsMarianne Oulhen, Patrycja Pawlikowska, Tala Tayoun, et al.
Cardiovascular and Interventional Radiology|November 7, 2019
Correction to: Focus on Recommendations for the Management of Non-small Cell Lung CancerPernelle Lavaud, Benjamin Besse, Thierry de Baere, et al.
Pageof 25

Showing results (91-100 of 243) with videos related to

Sort By:
Pageof 25
European Journal of Cancer (Oxford, England : 1990)|April 16, 2023
Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: real-world dataAlice Boilève, Matthieu Faron, Sarah Fodil-Cherif, et al.
Nature Communications|September 2, 2021
Integrin-α<sub>V</sub>-mediated activation of TGF-β regulates anti-tumour CD8 T cell immunity and response to PD-1 blockadeInes Malenica, Julien Adam, Stéphanie Corgnac, et al.
JAMA Network Open|September 10, 2025
Concomitant Comedications and Survival With First-Line Pembrolizumab in Advanced Non-Small-Cell Lung CancerAdrien Rousseau, Noémie Simon-Tillaux, Stefan Michiels, et al.
Clinical and Translational Radiation Oncology|May 19, 2023
Stereotactic body radiotherapy for extra-cranial oligoprogressive or oligorecurrent small-cell lung cancerAntonin Levy, Jonathan Khalifa, Etienne Martin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 17, 2019
Characterization, Prognosis, and Treatment of Patients With Metastatic Lung Carcinoid TumorsPatrick Robelin, Julien Hadoux, Julien Forestier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 15, 2013
Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancerEmma Pailler, Julien Adam, Amélie Barthélémy, et al.
Frontiers in Immunology|November 10, 2022
Immune-related arthritis following pelvic radiation therapy in a patient with lung cancer receiving long-term immune checkpoint blocker treatment: Case reportMihaela Aldea, Rakiba Belkhir, Emeline Colomba, et al.
Cancer Chemotherapy and Pharmacology|February 24, 2016
Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studiesDavid Planchard, Kathryn H Brown, Dong-Wan Kim, et al.
NPJ Precision Oncology|July 17, 2021
Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitorsMarianne Oulhen, Patrycja Pawlikowska, Tala Tayoun, et al.
Cardiovascular and Interventional Radiology|November 7, 2019
Correction to: Focus on Recommendations for the Management of Non-small Cell Lung CancerPernelle Lavaud, Benjamin Besse, Thierry de Baere, et al.
Pageof 25